

Gene therapy formulation

Optimize quality & potency across AAV serotypes & scales



Formulation screening

- High-throughput screening
- Forced degradation studies
- Long-term stability studies



Supportive studies

- Filter & mixing studies
- Manufacturing compatibility
- Hold-time studies




In-use studies

- Device compatibility
- Dosing procedure suitability

Gene therapy formulation that is closely linked to downstream & analytical processes

- Buffer & excipient selection
- Stability testing
- Confirmation of device compatibility & dosing procedure
- Low-volume high-throughput for better results from less material
- Rapid rebuffering & analytical testing
- Shorter development cycles & reduced barriers to final formulation
- Collaborative regulatory data documentation & submission

Proven Formulation Expertise




Before vs. after optimization of PS80 levels in an AAV formulation

Advanced Analytics & Developability

Formulation development is tightly intertwined with the analytical and downstream departments to tailor processes and streamline tech transfer.



Gyros ELISA



NanoDSF



DLS



Stunner



BMI



UNAGI Automated Rebuffering



ascend-adv.com business@ascend-adv.com

ADVANCED THERAPY MANUFACTURING SPECIALISTS

Aim higher

